hsa‐miR‐500a‐3P alleviates kidney injury by targeting MLKL‐mediated necroptosis in renal epithelial cells

What is it about?

In the current study, we found that hsa-miR-500a-3P, a miRNA decreased in cisplatin or NaN3-treated tubular epithelial cells, suppressed the MLKL expression by binding to its 3'-UTR, and thereby attenuated cisplatin-induced programmed cell death and NF-κB-driven renal inflammation in tubular epithelial cells. To our knowledge, It's the first miRNA which can suppress necroptosis by directly interacting with MLKL. Additionally, circulating exosomes from AKI patients induced the downregulation of miR-500a-3P and tubular epithelial cell injury in HK2 cells, indicating that miR-500a-3P had a negative correlation with renal injury, and it may serve as a potential therapeutic target in clinical setting

Featured Image